Chronic naltrexone treatment of rats: effects on gastrointestinal opioid peptide content.
The gastrointestinal tract contains immunoreactive enkephalins and beta-endorphin. The objective of the current study was to determine whether chronic treatment of rats with naltrexone altered the gastrointestinal tissue content of these opioid peptides. Opioid activity measured by radioreceptor assay was detectable throughout the gastrointestinal tract. There were regional differences in the [Met5]enkephalin: [Leu5]enkephalin-immunoreactivity (IR) ratios, possibly due to cell specific differential processing of precursor molecules or degradation of the peptides. Chronic naltrexone treatment increased opioid activity in the duodenum and jejunum, decreased [Met5]enkephalin-IR in the duodenum and [Leu5]enkephalin-IR in the gastric corpus, and increased beta-endorphin-IR in the duodenum. However, the changes were small, and it is unlikely that any functional changes resulting from naltrexone treatment can be reliably ascribed to such changes in tissue content.
McIntosh
C H
CH
Department of Physiology, University of British Columbia, Vancouver, Canada.
Law
S
S
Bakich
V
V
D000818:Animals; D004064:Digestive System / Q000187:drug effects* / Q000378:metabolism; D004386:Duodenum / Q000187:drug effects / Q000378:metabolism; D004743:Enkephalin, Leucine / Q000378:metabolism; D004744:Enkephalin, Methionine / Q000378:metabolism; D004745:Enkephalins / Q000378:metabolism*; D007583:Jejunum / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009271:Naltrexone / Q000494:pharmacology*; D011706:Pyloric Antrum / Q000187:drug effects / Q000378:metabolism; D011863:Radioimmunoassay; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D001615:beta-Endorphin / Q000378:metabolism*
D004745:Enkephalins; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; D009271:Naltrexone; D001615:beta-Endorphin